Abstract:Immune-checkpoint inhibitor-based combination immunotherapy has become a first-line treatment for several major types of cancer including hepatocellular carcinoma (HCC), renal cell carcinoma, lung cancer, cervical cancer, and gastric cancer. Combination immunotherapy counters several immunosuppressive elements in the tumor microenvironment and activates multiple steps of the cancer-immunity cycle. The anti-PD-L1 antibody, atezolizumab, plus the anti-vascular endothelial growth factor antibody, bevacizumab, represents a promising class of combination immunotherapy. This combination has produced unprecedented clinical efficacy in unresectable HCC and become a landmark in HCC therapy. Advanced HCC patients treated with atezolizumab plus bevacizumab demonstrated impressive improvements in multiple clinical endpoints including overall survival, progress-free survival, objective response rate, and patient-reported quality of life when compared to current first-line treatment with sorafenib. However, atezolizumab plus bevacizumab first-line therapy has limitations. First, cancer patients falling into the criteria for the combination therapy may need to be further selected to reap benefits while avoiding some potential pitfalls. Second, the treatment regimen of atezolizumab plus bevacizumab at a fixed dose may require adjustment for optimal normalization of the tumor microenvironment to obtain maximum efficacy and reduce adverse events. Third, utilization of predictive biomarkers is urgently needed to guide the entire treatment process. Here we review the current status of clinically approved combination immunotherapies and the underlying immune mechanisms. We further provide a perspective analysis of the limitations for combination immunotherapies and potential approaches to overcome the limitations.

Advances of combined immunotherapy in tumor

Combined Targeted Therapy and Immunotherapy for Cancer Treatment

Tumor Immune Checkpoints and Their Associated Inhibitors

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions

Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors

The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment

Advances in treatment of melanoma with immunotherapy

Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy

Combined with Interventional Therapy, Immunotherapy Can Create a New Outlook for Tumor Treatment.

Immunotherapy: cancer immunotherapy and its combination with nanomaterials and other therapies

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy

Clinically approved combination immunotherapy: Current status, limitations, and future perspective

Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody−Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects

Emerging strategies in cancer therapy combining chemotherapy with immunotherapy.

Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors.

Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy

Emerging immune checkpoint and its combination therapy in cancer treatment

The New Progress in Cancer Immunotherapy